



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

#6

APPLICANTS: Brian Lauman, et al.

GROUP ART UNIT: 3763
CONFIRMATION NO.: 1135
EXAMINER: Not yet assigned

SERIAL NO.: 10/051,609

ATTY. DOCKET NO.: DI-5764

FILING DATE: January 17, 2002

MAIL STOP DD
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

RECEIVED
APR 21 2003
TECHNOLOGY CENTER R3700

Dear Sir/Madam:


Submitted herewith is a Supplemental Information Disclosure Statement for consideration in the above-identified application. This Supplemental Information Disclosure Statement is submitted:

- ☒ Within 3 months (1) of filing date of a national application; (2) of date of entry of the national stage as set forth in 37 CFR §1.491 in an international application; or (3) before the mailing date of a first Office Action on the merits, whichever occurs last. (No fee is required.)
- ☐ After the mailing date of a first Office Action but before (1) mailing of a final action under 37 CFR §1.311, whichever occurs first.
- ☐ Please charge payment for the fee set forth in 37 CFR §1.17(i)(1) to Deposit Account No. 02-1444.
- ☒ The certification specified in 37 CFR §1.97(e) is made below. (No fee is required.)
- ☐ After the mailing of (1) a final action under 37 CFR §1.113; or (2) a notice of allowance under 37 CFR §1.311 whichever occurs first, but before payment of the issue fee. The certification specified in 37 CFR §1.97(e) is made below. The Commissioner hereby is petitioned to consider the Information Disclosure Statement accompanying the submission.
- ☒ The undersigned counsel for applicant(s) hereby certifies each item of information identified in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ The undersigned counsel for applicant(s) hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, or to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the statement.
- ☒ The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Account No. 02-1444. A duplicate copy of this sheet is enclosed for this purpose.

Very respectfully,


Baxter Healthcare Corporation

When phoning re this application,
please call (847) 948-3315


Joseph P. Reagen
Baxter Healthcare Corporation
One Baxter Parkway, DF3-3E
Deerfield, Illinois 60015
Telephone: (847) 948-3315

Reg. No. 35,332

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Arlington, VA on April 15, 2003.


Joseph P. Reagen

Reg. No. 35,332

